Evaluation of apoptosis as a prognostic factor in myelodysplastic syndromes

British Journal of Haematology

Volumn 110, Issue 3, 2000, Pages 584-590

  Shimazaki, K ^a   Ohshima, K ^a   Suzumiya, J ^a   Kawasaki, C ^a   Kikuchi, M ^a  

^a FUKUOKA UNIVERSITY   (Japan)

Author keywords

Apoptosis; CD34; MDS; MIB 1; Prognostic factor

Indexed keywords

CD34 ANTIGEN; DNA FRAGMENT; MONOCLONAL ANTIBODY KI 67;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; BONE MARROW BIOPSY; CELL PROLIFERATION; CHRONIC MYELOMONOCYTIC LEUKEMIA; COMORBIDITY; CONTROLLED STUDY; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PANCYTOPENIA; PRIORITY JOURNAL; PROGNOSIS; REFRACTORY ANEMIA; SIDEROBLASTIC ANEMIA;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD34; ANTIGENS, NUCLEAR; APOPTOSIS; BIOLOGICAL MARKERS; BONE MARROW CELLS; EVALUATION STUDIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; KI-67 ANTIGEN; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NUCLEAR PROTEINS; PROGNOSIS; SURVIVAL RATE;

EID: 0033781130     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2000.02228.x     Document Type: Article

References (25)

1. Sultan C. Proposals for the classification of the myelodysplastic syndromes
2. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodyplastic syndromes
3. The treatment of anaemia in the myelodysplastic syndromes
4. Erythroid and myeloid maturation patterns related to progenitor assessment in the myelodysplastic syndromes
5. The origins of DNA breaks: A consequence of DNA repair or apoptosis?
6. Identification of programmed cell death in situ via specific labelling of nuclear DNA fragmentation
7. International scoring system for evaluating prognosis in myelodysplastic syndromes
8. Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoietin
9. Advances and controversies in the study of programmed cell death/apoptosis in the development of and therapy for cancer
10. Measurement of proliferation activities in human tumor models: A comparison of flow cytometric methods
11. Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoiesis and a high incidence of p53 mutations
12. Is apoptosis a massive process in myelodysplastic syndromes?
13. In situ end labeling DNA to detect apoptotic cell death in a variety of tumors
14. p53 Overexpression in myeloid leukemic disorder is associated with increased apoptosis of hematopoietic marrow cells and ineffective hematopoiesis
15. Bone marrow histology and CD34 immunostaning in the prognostic evaluation of primary myelodysplastic syndromes
16. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells
17. Cell cycle kinetic studies in human cancers. Development of three DNA-specific labels in three decades
18. In situ cell cycle kinetics in bone marrow biopsies following sequential infusions of IudR/BrdU in patients with hematopoietic malignancies
19. Simultaneous assessment of cell kinetics and programmed cell death in bone marrow biopsies of myelodysplastics reveals extensive apoptosis as the probable basis for ineffective hematopoiesis
20. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes
21. Recommendations for a morphologic, immunologic, and cytogenetic (MIC) working classification of the primary and therapy-related myelodysplastic disorders. Report of the workshop held in Scottsdale, Arizona, USA, on February 23-25, 1987
22. Modifications in the classification of primary myelodysplastic syndromes: The addition of a scoring system
23. A new method to detect apoptosis in paraffin section: In situ end-labeling of fragmented DNA
24. Hypothesis: Apoptosis may be the mechanism responsible for the premature intramedullary cell death in the myelodysplastic syndromes
25. Apoptosis in myelodysplasia: A paradox or a paradigm